Bionano Genomics Inc (BNGO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Bionano Genomics Inc stock (BNGO) is currently trading at $1.20. Bionano Genomics Inc PS ratio (Price-to-Sales) is 0.39. Analyst consensus price target for BNGO is $5.50. WallStSmart rates BNGO as Sell.
- BNGO PE ratio analysis and historical PE chart
- BNGO PS ratio (Price-to-Sales) history and trend
- BNGO intrinsic value — DCF, Graham Number, EPV models
- BNGO stock price prediction 2025 2026 2027 2028 2029 2030
- BNGO fair value vs current price
- BNGO insider transactions and insider buying
- Is BNGO undervalued or overvalued?
- Bionano Genomics Inc financial analysis — revenue, earnings, cash flow
- BNGO Piotroski F-Score and Altman Z-Score
- BNGO analyst price target and Smart Rating
Bionano Genomics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Bionano Genomics Inc (BNGO) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, revenue growth. Concerns around market cap and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Bionano Genomics Inc (BNGO) Key Strengths (3)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Strong revenue growth at 21.30% annually
Supporting Valuation Data
Bionano Genomics Inc (BNGO) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very low institutional interest at 10.61%
Micro-cap company with very limited liquidity and high volatility
Bionano Genomics Inc (BNGO) Detailed Analysis Report
Overall Assessment
This company scores 37/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 9.3/10) while 5 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book, Revenue Growth. Valuation metrics including Price/Sales (0.39), Price/Book (0.23) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 21.30%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Profitability pressure is visible in Return on Equity at -78.20%, Operating Margin at -115.90%, Profit Margin at -134.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -78.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 21.30% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BNGO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BNGO's Price-to-Sales ratio of 0.39x sits near its historical average of 0.38x (57th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 3% below its historical high of 0.4x set in Mar 2026, and 5% above its historical low of 0.37x in Mar 2026.
Compare BNGO with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Bionano Genomics Inc (BNGO) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Bionano Genomics Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 29M with 21% growth year-over-year. The company is currently unprofitable, posting a -134.4% profit margin.
Key Findings
Debt-to-equity ratio of 0.15 indicates a conservative balance sheet with 3M in cash.
The company is unprofitable with a -134.4% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -4M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Bionano Genomics Inc maintain 21%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.72, so expect amplified moves relative to the broader market.
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Bionano Genomics Inc.
Bottom Line
Bionano Genomics Inc offers an attractive blend of growth (21% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Bionano Genomics Inc(BNGO)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Bionano Genomics, Inc. is a life science instrumentation company in the genome analysis space. The company is headquartered in San Diego, California.